Axatilimab, an anti-CSF-1R antibody, has demonstrated efficacy in patients with recurrent or refractory chronic graft-vs-host disease (GVHD), according to a presentation at the ASH Annual Meeting 2023.
Axatilimab produced “rapid and durable” responses and proved “highly effective” when given at 0.3 mg/kg every 2 weeks, said study presenter Daniel Wolff, MD, PhD, of the University Hospital Regensburg in Germany Axatilimab Proves “Highly Effective” in Recurrent/Refractory Chronic GVHD – Cancer Therapy Advisor
